Four studies [11, 13–15] investigated HCC patients undergoing immunotherapy; immunotherapeutic regimens included anti-programmed death (ligand) 1 (anti-PD-(L)1)-based immunotherapy monotherapy plus bevacizumab/ramucirumab/TKI and anti-CTL-4/anti-CD38. Here, CD274 is linked to hepatocellular carcinoma.